GSK wins FDA approval of Blenrep for multiple myeloma
Source: SeekingAlpha
2025-10-23 17:27:02 ET
More on GSK
- GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon
- GSK's Hidden Growth Engines Beyond HIV And Oncology
- GSK: Walmsley Out, Miels In - I'm Watching The CEO Transition From The Sidelines
- Alector slumps on late-stage trial setback for GSK-partnered dementia candidate
- Astra, GSK up after report on U.K. – U.S. drug pricing deal
Read the full article on Seeking Alpha
For further details see:
GSK wins FDA approval of Blenrep for multiple myeloma
National Vision Holdings Inc.
NASDAQ: EYE
EYE Trading
0.63% G/L:
$26.52 Last:
406,025 Volume:
$26.18 Open:
EYE Latest News
EYE Stock Data
$2,199,254,043
77,168,200
0.02%
93
N/A
Retail - Discretionary
Consumer Discretionary
US
Duluth
